Novo Nordisk to cut Wegovy U.S. list price from 2027

Novo Nordisk said it will halve Wegovy's U.S. list price starting January 1, 2027, and set Ozempic and Wegovy at $675 per month.

Novo Nordisk announced on Tuesday that it will cut U.S. list prices for several GLP-1 medicines beginning January 1, 2027. The change includes halving the list price of Wegovy and lowering the list price of Ozempic, with both set to list at $675 per month. The timing coincides with new, lower prices for the same drugs under federal Medicare plans for older adults, the article said. The report also notes increasing competition in the GLP-1 market and a broader shift toward cash-pay channels. Key facts: - Novo Nordisk will list Ozempic and Wegovy at $675 per month in the U.S. starting January 1, 2027. - The move halves Wegovy's current list price and represents about a 35% cut for Ozempic, according to the article. - The price reductions also apply to Wegovy and Rybelsus pills and to all doses of the medicines. - The change aligns with new lower Medicare prices for the drugs for older adults, the article said. - The company said the decision reflects a commitment to enhancing affordability for patients and public and private payers. Summary: The change lowers headline list prices for widely used GLP-1 medicines and brings private list pricing into step with newly reduced Medicare pricing, as reported. Undetermined at this time whether further pricing actions or broader market impacts will follow.